CognitiveMedium Risk
Dihexa
Also known as: PNB-0408
- Half-life:
- Unknown (likely days based on effects)
Administration Routes
oraltransdermalsubcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models
An extremely potent cognitive enhancer that promotes synaptogenesis and neuroplasticity. Shows remarkable results in Alzheimer's and cognitive decline models.
Primary Research Areas
- synaptogenesis
- memory enhancement
- cognitive repair
- neurogenesis
Risk Profile
Medium Risk
Moderate risk profile in research contexts. Consult a healthcare professional before use.
Regulatory Status
Research OnlyNot Evaluated by FDA
Angiotensin IV-derived hexapeptide (PNB-0408) from WSU research. Cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Research compound only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.